ALX Oncology reports Phase 2 failures for CD47 drug combo with Keytruda
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump. The company said Friday that two trials testing different combinations of its CD47-targeting drug failed to meet their ...
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump.
The company said Friday that two trials testing different combinations of its CD47-targeting drug failed to meet their ...
